Goldman Sachs Downgrades Reata Pharmaceuticals (RETA) to Neutral
Tweet Send to a Friend
Goldman Sachs analyst Salveen Richter downgraded Reata Pharmaceuticals (NASDAQ: RETA) from Buy ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE